H. pylori rescue eradication therapy with lascufloxacin, amoxicillin, and vonopraza

Phase 2

Recruiting

• Conditions: Helicobacter pylori infection; Helicobacter pylori

• Registration Number: JPRN-jRCTs031200154
• Lead Sponsor: Sue Soichiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

(1)Patients diagnosed with Helicobacter pylori infection
(2)Patients with clarithromycin and metronidazole resistant H. pylori infection or patients who failed eradication by both triple therapy with clarithromycin and amoxicillin and triple therapy with metronidazole and amoxicillin.

Exclusion Criteria

(1)Past history of allergy for vonoprazan, amoxicillin, or lascufloxacin.
(2)Patients with infectious mononucleosis.
(3)Patients taking atazanavir or rilpivirine.
(4)Pregnancy.
(5)Lactation.
(6)Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction.
(7)Patients who are disqualified for the study by physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified